CoreCap Advisors’s Caribou Biosciences CRBU Stock Holding History

CoreCap Advisors’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-4,476	Closed	-$4.09K	–	2868
2025 Q1	$4.09K	Buy	+4,476	New	+$5.82K	﹤0.01%	2149

Other funds holding CRBU

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CoreCap Advisors's CRBU Position: Q2 2025 in Review

CoreCap Advisors sold out of Caribou Biosciences (CRBU) in Q2 2025, closing a stake of 4,476 shares — an estimated $4.09K sold.

CoreCap Advisors first reported a position in CRBU in Q1 2025 and held it in 1 quarter. The position peaked at $4.09K in Q1 2025. 129 funds tracked by Wall St. Rank hold CRBU as of Q2 2025.

CoreCap Advisors reported no remaining Caribou Biosciences position as of Q2 2025 after selling out during the quarter.
CoreCap Advisors sold 4,476 Caribou Biosciences shares in Q2 2025, an estimated $4.09K.
CoreCap Advisors first reported a position in Caribou Biosciences in Q1 2025 and held it in 1 quarter.
CoreCap Advisors's Caribou Biosciences position peaked at $4.09K in Q1 2025.
129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.